Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Admittedly for Wiki so fair warning
"Specific cysteine residues can be introduced to the protein to allow thiol chemistry to uniformly orient Affimer proteins on a solid support for the purposes of increasing target capture in ligand binding assays and biosensors"
So its important the maximum numbers of binding sites are presented to the antigen. Random distribution (such as spraying on to a surface and taking what you get) would limit this. By being able to orientate all the binding sites in the optimum place then the limit of detection and ability to distinguish between different
concentrations (is that sensitivity?) Is improved.
Still not proven first covid but maybe for Zika. Given this element of structure of affirmers is consistent then looking good - zika project not commercially a success but probably shortened development times.
IF we get a successful covid test then actually what we have is a whole new class of diagnostics which will threaten the existing Ab based tests. Companies such as Abbott etc must have done a Porters 5 forces (been dying to use that just to confuse Nelly the jolliphant) and be thinking how to respond. Choices limited cause of patent on molecule class.
Yeeeeeeeeee hah
Not a molecular scientist
Thank for posting lists with dates - looks good to me. Not a lawyer.
Now there's obviously a paper chain for a better mind than me but
https://biologicalsciences.leeds.ac.uk/molecular-and-cellular-biology/staff/145/dr-tomlinson
Professor Tomlinson started off in Edinburgh then went to Leeds who appear to have picked up the affimer baton. Oops required to stand in a queue :(
Phantom25
I'm sure you've already read the wiki page but for anybody that hasn't me until 15 mins ago!! Go under developments.
https://en.wikipedia.org/wiki/Affimer
Now I've got various tabs open.
Phantom25,
This might help answer your question.
https://avacta.com/about/intellectual-property/
Strength of IP is an important consideration. Given how long company has been up and running do we have any dates.
Medusa19 has the exclusive distribution rights to directly deliver to consumers a saliva based rapid test, currently under development by Avacta Group Plc, for the COVID-19 antigen, subject to regulatory approval. As such, its immediate priority is to invest in the necessary functions that will enable Avacta’s test to be rapidly and globally deployed once it becomes available.
Hi Ken
A quick question, i am aware that Avacta hold patents on Affimers. How did they manage this when they were first developed by the MRC. Did they purchase the rights? or fund the initial project. And do they have rights on everything 'Affirmer' or just the implementation of them in their field
The most important point is Avacta owns the patent and the trademark to Affimer Technology, so if we consider the number of opportunities available to them where they can be used for diagnostics and in therapeutics they have everything in their control. That is why they want partnerships! The opportunities to fast track growth when you have the ability to develop solutions in around 8 weeks to new requirements which can then be marketed those to various clients who then have to pay the company for their use becomes one hugely valuable asset.
The only way the competion has to take on Avacta is to have a different solution which doesn’t impede the patent and that will be very difficult!
In this case the intellectual property is with the scientists. Even buying the business, if you don’t have the people it is not worth the acquisition! So for shareholders including company directors who hold that is very good news.
If we end up with multiple giant pharmaceutical companies all partnering with Avacta the sky is the limit here. Once they have on each project the approvals and certification then the number of opportunities for infinite revenue streams is enormous.
If they get this right in a few years time they could (not saying they will) become one of the most important and valuable Biotech companies in the world!
The weeks ahead are going to be very exciting indeed. For any who are new to this forum and want to see the multiple oppertunities, please do watch this presentation:
https://webcasting.brrmedia.co.uk/broadcast/5e985bc231da814c9fc6a477/5e9d8891f43115b1470001c7
I am very pleased I found this great opportunity and I hope you will be!
Cheers RK